The INPP5E Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used HeLa cervical adenocarcinoma line. These cells harbor disruptions in the INPP5E gene, providing a loss-of-function model for studying INPP5E biology. As a polyclonal pool, they capture allelic heterogeneity, suitable for population-level functional analyses. The polyclonal population reflects diverse knockout alleles, mimicking genetic heterogeneity present in natural populations.
HeLa is an aneuploid, immortalized epithelial line transformed by HPV18 E6/E7 oncogenes, which inactivate p53 and RB tumor suppressors, respectively. This cell line exhibits high proliferative capacity and tumorigenicity, and is a foundational model for cancer research, signal transduction, and cell biology.
INPP5E is a lipid phosphatase that hydrolyzes the 5-phosphate of PIP3 and PI(3,5)P2, yielding PI(3,4)P2 and PI(3)P respectively. This activity dampens PI3K-dependent AKT signaling, thereby regulating downstream effectors PDK1, mTORC1, FOXO, and cell cycle machinery. Localized to the primary cilium, INPP5E also modulates Hedgehog pathway output by influencing GLI transcription factor processing through interactions with ciliary trafficking proteins PDE6D, ARL13B, and IFT complexes. It is activated by PI3K and growth factors including EGF and IGF-1, and functionally opposes PTEN, a 3-phosphatase. Cooperation with Hedgehog components SMO and PTCH1 connects phosphoinositide metabolism to ciliogenesis and developmental signaling pathways. Consequently, INPP5E deficiency leads to persistent AKT activation and altered GLI-mediated transcription, which can be monitored via phospho-signaling and Hedgehog target gene expression assays.
In HeLa cells, INPP5E loss generates a hyperactivated PI3K/AKT context, enabling dissection of how HPV18 oncoproteins cooperate with phosphoinositide signaling. HeLa cells form primary cilia, permitting investigation of ciliary INPP5E function and Hedgehog dysregulation in a cancer-relevant setting. This model is valuable for bridging ciliopathy mechanisms with tumor cell biology.
Applications encompass PI3K/AKT inhibitor screening, PIP3 quantification, and Hedgehog pathway readouts such as RT-qPCR of GLI1 and PTCH1. Immunofluorescence for ciliary markers ARL13B and IFT88, flow cytometric cell cycle analysis, and migration assays are routinely performed. The cells serve as a platform for therapeutic testing in Joubert syndrome and MORM syndrome research, as well as general ciliopathy studies. For further information, please contact Ascent Research.
